Felix Geissler
Geen lopende functies
Profiel
Felix Geissler served as Vice President-Medical Affairs at Curis, Inc. in 2022-2023.
Prior to that, he held the same position at Horizon Therapeutics Plc.
He also served as Chief Medical Officer at Lumicell, Inc. and as SVP, Head-Oncology, Hematology & Transplant at Sanofi Corp.
Geissler holds a doctorate degree from the University of Innsbruck, Eberhard Karls Universität Tübingen, and Ludwig-Maximilians-Universität München.
Eerdere bekende functies van Felix Geissler
Bedrijven | Functie | Einde |
---|---|---|
CURIS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2023 |
Sanofi Corp. | Corporate Officer/Principal | - |
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Lumicell, Inc. develops and markets image-guided cancer surgery solutions. It offers Lumicell System, designed to enable surgeons to see residual cancer cells in the cavity walls in real-time during surgery. The company was founded by Linda G. Griffith, David G. Kirsch, Jorge M. Ferrer, Ralph Weissleder, W. David Lee, Andrey J. Zarur, and Moungi G. Bawendi in 2008 and is headquartered in Wellesley, MA. | Hoofd Techniek/Wetenschap/O&O | - |
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Felix Geissler
University of Innsbruck | Doctorate Degree |
Eberhard Karls Universität Tübingen | Doctorate Degree |
Ludwig-Maximilians-Universität München | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
CURIS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Lumicell, Inc. develops and markets image-guided cancer surgery solutions. It offers Lumicell System, designed to enable surgeons to see residual cancer cells in the cavity walls in real-time during surgery. The company was founded by Linda G. Griffith, David G. Kirsch, Jorge M. Ferrer, Ralph Weissleder, W. David Lee, Andrey J. Zarur, and Moungi G. Bawendi in 2008 and is headquartered in Wellesley, MA. | Electronic Technology |
Sanofi Corp. |